NCT06966687View on ClinicalTrials.gov

Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI)

NAEnrolling by invitationINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Aortic DissectionAortic Dissection Aneurysm
Interventions
DRUG

Ulinastatin and Thymosin α1

Ulinastatin (100000U TID for 5 days) and Thymosin alpha 1 (1.6 mg q12h for 5 days) immediately after surgery

DRUG

Ulinastatin only

Ulinastatin (100000U TID for 5 days) immediately after surgery

Trial Locations (4)

Unknown

Beijing Anzhen Hospital, Beijing

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Shanghai East Hospital Tongji University, Shanghai

West China Hospital, Chengdu

Sponsors
All Listed Sponsors
collaborator

Beijing Anzhen Hospital

OTHER

collaborator

West China Hospital

OTHER

collaborator

Shanghai East Hospital,Tongji University School of Medicine

UNKNOWN

collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Nanjing Medical University

OTHER